MannKind closed 2025 on a high note, marked by milestones that reinforce our growth trajectory—including the acquisition of scPharmaceuticals and a record-setting fourth quarter surpassing $100 ...
News-Medical.Net on MSN
Self-administered injectable contraceptives face provider hesitancy despite availability
Self-administered injectable contraceptives have been available in the United States for more than two decades, yet a new ...
Atacicept, a novel dual inhibitor of BAFF and APRIL, receives FDA Priority Review for IgA nephropathy treatment in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback